A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center.
The results were presented in the virtual 25th European Hematology Association (EHA) Annual Congress and were published today in the New England Journal of Medicine...
The University of Texas MD Anderson Cancer Center is committed to safely providing patient care and cancer screenings throughout the novel...
According to researchers from The University of Texas MD Anderson Cancer Center, the implementation of social distancing policies corresponded...
The University of Texas MD Anderson Cancer Center is honored to rank No. 1 in cancer care in the U.S. News & World Report’s 2020-21 “Best Hospitals” survey. The institution has been named one of the nation’s top two cancer hospitals since the survey’s inception in 1990.
“This incredible honor is especially impactful during these unprecedented times,” said Peter WT Pisters, M.D., president, MD Anderson. “We are extremely...
The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development...
The University of Texas MD Anderson Cancer Center and two institutions at The University of Texas at Austin – the Oden Institute for Computational...
Public Notice
MAGNET RECOGNITION PROGRAM® — SITE VISIT
· The University of Texas...
In the first study to look at objective measures of sedentary behavior and cancer mortality, researchers from The University of Texas MD Anderson...
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical...
The University of Texas MD Anderson Cancer Center and Royal Philips today announced a collaboration to provide oncologists with evidence-based...